Bayer's riociguat meets Phase III endpoint in PAH
This article was originally published in Scrip
Executive Summary
Bayer HealthCare said it is planning to submit marketing authorisation applications in the first half of 2013 for its first-in-class guanylate cyclase stimulator vasodilator, riociguat, after reporting that a Phase III pulmonary arterial hypertension (PAH) trial has met the primary endpoint.